Literature DB >> 27558206

Modest improvement in survival of patients with refractory anemia with excess blasts in the hypomethylating agents era in the United States.

Amer M Zeidan1,2, Rong Wang2,3, Cary P Gross2, Steven D Gore1,2, Scott F Huntington1,2, Thomas Prebet1, Gregory A Abel4, Amy J Davidoff2,5, Xiaomei Ma2,3.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27558206     DOI： 10.1080/10428194.2016.1214954

Source DB:  PubMed          Journal:  Leuk Lymphoma        ISSN： 1026-8022


× No keyword cloud information.
  7 in total

1.  Hypomethylating agent (HMA) therapy use and survival in older adults with Refractory Anemia with Excess Blasts (RAEB) in the United States (USA): a large propensity score-matched population-based study†.

Authors:  Amy J Davidoff; Xin Hu; Jan Philipp Bewersdorf; Rong Wang; Nikolai A Podoltsev; Scott F Huntington; Steven D Gore; Xiaomei Ma; Amer M Zeidan
Journal:  Leuk Lymphoma       Date:  2019-12-26

2.  Long-term survival of older patients with MDS treated with HMA therapy without subsequent stem cell transplantation.

Authors:  Amer M Zeidan; Maximilian Stahl; Xin Hu; Rong Wang; Scott F Huntington; Nikolai A Podoltsev; Steven D Gore; Xiaomei Ma; Amy J Davidoff
Journal:  Blood       Date:  2017-12-19       Impact factor: 22.113

3.  Comparison of clinical outcomes and prognostic utility of risk stratification tools in patients with therapy-related vs de novo myelodysplastic syndromes: a report on behalf of the MDS Clinical Research Consortium.

Authors:  A M Zeidan; N Al Ali; J Barnard; E Padron; J E Lancet; M A Sekeres; D P Steensma; A DeZern; G Roboz; E Jabbour; G Garcia-Manero; A List; R Komrokji
Journal:  Leukemia       Date:  2017-01-23       Impact factor: 11.528

4.  More is less, less is more, or does it really matter? The curious case of impact of azacitidine administration schedules on outcomes in patients with myelodysplastic syndromes.

Authors:  Rory M Shallis; Amer M Zeidan
Journal:  BMC Hematol       Date:  2018-02-01

5.  A randomized phase 2 trial of azacitidine with or without durvalumab as first-line therapy for higher-risk myelodysplastic syndromes.

Authors:  Amer M Zeidan; Isaac Boss; C L Beach; Wilbert B Copeland; Ethan Thompson; Brian A Fox; Vanessa E Hasle; Ken Ogasawara; James Cavenagh; Lewis R Silverman; Maria Teresa Voso; Andrzej Hellmann; Mar Tormo; Tim O'Connor; Alessandro Previtali; Shelonitda Rose; Guillermo Garcia-Manero
Journal:  Blood Adv       Date:  2022-04-12

Review 6.  Treatment of myelodysplastic syndromes in the era of precision medicine and immunomodulatory drugs: a focus on higher-risk disease.

Authors:  Razan Mohty; Rama Al Hamed; Ali Bazarbachi; Eolia Brissot; Arnon Nagler; Amer Zeidan; Mohamad Mohty
Journal:  J Hematol Oncol       Date:  2022-08-31       Impact factor: 23.168

7.  Counseling patients with higher-risk MDS regarding survival with azacitidine therapy: are we using realistic estimates?

Authors:  Amer M Zeidan; Maximilian Stahl; Michelle DeVeaux; Smith Giri; Scott Huntington; Nikolai Podoltsev; Rong Wang; Xiaomei Ma; Amy J Davidoff; Steven D Gore
Journal:  Blood Cancer J       Date:  2018-06-11       Impact factor: 11.037
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.